BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

BIOREM Technologies Inc. Announces First Quarter Results


5/31/2012 12:23:12 PM

GUELPH, ON, May 30, 2012 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) announced today its results for the first quarter of 2012:

First quarter ended March31,
Information in table is in thousands except per share data 20122011
REVENUE $3,267 $3,732
GROSS PROFIT 380 1,366
RESULTS FROM OPERATING ACTIVITIES (483) 93
NET EARNINGS (LOSS) (544) (19)
BASIC EARNINGS PER SHARE (0.04) 0.00
DILUTED EARNINGS PER SHARE (0.04) 0.00

Q1, 2012 revenue was $3,267,000, which is down $465,000 or 12.5% over the comparative period in the prior year. New orders in the quarter were $4.0 million resulting in a backlog increase of 0.7 million to $15.7 million. This compares to $2.8 million in bookings and a period ending backlog of $10.6 million in Q1, 2011.Gross Profit in the quarter was $380,000, or 11.6% of revenues compared to $1,366,000 or 36.6% of revenues in the same period in prior year.

Total Net Loss was $544,000 in the first quarter compared to a loss of $19,000 in the comparative period from last year. Total operating costs for the period were $863,000 compared with an operating cost of $1,272,000 in 2011, for a reduction of $409,000.

"While our results from the quarter have come in near our expectations, our gross profits in Q1 were lower primarily due to the completion of a large, low margin project taken last year in support of developing the biogas market." said Peter Bruijns, President and CEO. "We have made considerable progress on reduction of costs and continue to focus on cash management, revenue growth as well as gross margin improvement."

During the quarter, cash and cash equivalents were reduced by $100,000.

Subsequent to the first quarter, the Company announced a proposed private placement of up to 1400 Units at $1,000 per Unit for gross proceeds of $1,400,000, each Unit consisting of 8% debentures and one common share purchase warrant. A total of 535 units were issued on May 4, 2012 for proceeds of $535,000. The Private Placement remains open until June 4, 2012 for additional investment. The Company has successfully renegotiated its existing 12.75% debenture agreement providing for new repayment terms and revised covenants.

About BIOREM Inc.
Biorem is a leading clean technology company that designs, manufactures and distributes a comprehensive line of high-efficiency biological-based air emissions control systems. These systems are used to eliminate odors, volatile organic compounds (VOCs) and hazardous air pollutants (HAPs), and for the conditioning of biogas renewable energy. With sales and manufacturing offices across the continent, a dedicated research facility, a worldwide sales representative network and more than 700 installed systems worldwide, Biorem not only offers state-of-the-art technology-based products but also peace of mind for municipalities, industrial companies and their surrounding communities. Additional information on Biorem is available on our website at www.biorem.biz.

The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. The TSX Venture Exchange Inc. has neither approved nor disapproved of the contents of this release.

Forward-Looking Statements
This press release contains forward-looking statements based on current expectations. These forward-looking statements contain various risks and uncertainties that could cause actual results to differ materially from those reflected in the forward-looking statements. Risks and uncertainties about the Company's business are more fully discussed in the disclosure materials, financial statements and MD&A filed with the securities regulatory authorities in Canada on www.sedar.com

Non-IFRS Measures

"Order Bookings" and "Order Backlog" do not have any standardized meaning prescribed by Canadian generally accepted accounting principles ("GAAP") and may not be comparable to measures presented by other companies. Order Bookings and Order Backlog are non-IFRS measures that the Company uses to evaluate its sales performance. Order Bookings are those binding contracts that the Company enters into with a third party for the delivery of our products or services. As Order Bookings are received, the contract value (before any associated sales taxes) is included in the Order Backlog. The Order Backlog is reduced by the revenue that is recognized on each project and then adjusted for any currency changes.

SOURCE Biorem Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES